Background
==========

Acute coronary syndrome (ACS) is the leading cause of death in patients with chronic kidney disease (CKD) \[[@B1],[@B2]\]. The severity of renal insufficiency, including mild to moderate renal insufficiency is directly associated with increased cardiovascular morbidity and mortality \[[@B3],[@B4]\]. Several factors may be related to poorer outcomes of ACS in patients with renal insufficiency. Hypertension, dyslipidemia, and diabetes mellitus (DM) are common among patients with renal insufficiency and are often inadequately treated in this population \[[@B5]\]. In addition, the accumulation of uremic toxins can stimulate oxidative stress and inflammation, and hence, contribute to endothelial dysfunction and atherosclerosis progression \[[@B6]\].

Primary management in patients with ST-segment elevation myocardial infarction (STEMI) includes timely restoration of flow in the stenosed artery---either by fibrinolysis or by percutaneous coronary intervention (PCI)---to limit the extent of infarction in the myocardium. In addition, medications (anti-platelet agent, β-blocker, angiotensin-converting enzyme \[ACE\] inhibitor or angiotensin-receptor blocker \[ARB\] and statin) form an important component of evidence-based management. These management strategies have contributed to improved survival in patients with STEMI. However, only a few studies have evaluated how renal function affects the likelihood of receiving optimal medical care throughout the entire treatment period in patients with STEMI.

The purpose of this study was to investigate whether renal insufficiency is associated with a decreased likelihood of receiving optimal medical care in patients with STEMI. The entire medical treatment process for patients with STEMI was comprehensively analyzed, and the relationship between optimal management and clinical outcomes in patients with renal insufficiency was investigated.

Methods
=======

Korea acute myocardial infarction registry
------------------------------------------

The study population was derived from the Korea Acute Myocardial Infarction Registry (KAMIR). The KAMIR is a prospective, open, observational, multicenter online registry investigating the risk factors for mortality in patients with acute myocardial infarction (AMI) in Korea since November 2005. Through the support of the Korean Circulation Society, 52 community and university hospitals that had facilities for primary PCI and sufficient experience with the procedure participated in KAMIR with the aim of establishing clinical practice guidelines for AMI. The name of each participation centers listed in the Appendix 1 and 2. Data were collected at each site by a trained study coordinator by using a standardized protocol. The study protocol was approved by the ethics committee at each participating institution. All patients gave written informed consent before enrollment.

Study population
----------------

This study retrospectively analyzed a cohort of 7,679 consecutive patients who were admitted to the hospital between November 1, 2005, and July 31, 2008, and had a discharge diagnosis of STEMI, confirmed by both cardiac enzyme and electrocardiogram analyses. The diagnosis of STEMI was based on a suggestive history, with ST elevation \> 2 mm in ≥2 precordial leads, ST elevation \> 1 mm in ≥2 limb leads, or new left branch bundle block on the 12-lead electrocardiogram with a concomitant increase of cardiac markers ≥2 times the upper limit of normal. Patients were excluded if an estimated glomerular filtration rate (GFR) could not be calculated.

Renal function was based on GFR estimation. The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation was used to estimate GFR in milliliters per minute per 1.73 m^2^\[[@B7]\]. The study population was divided into 5 groups according to the estimated GFR: group I, GFR ≥ 90 mL/min/1.73 m^2^ (2099 patients; age, 54 ± 11 years; men, 83.1%); group II, 60 ≤ GFR \< 90 mL/min/1.73 m^2^ (3647 patients; age, 63 ± 12 years; men, 75.8%); group III, 30 ≤ GFR \< 60 mL/min/1.73 m^2^ (1600 patients; age, 71 ± 11 years; men, 60.6%); group IV, 15 ≤ GFR \< 30 mL/min/1.73 m^2^ (210 patients; age, 73 ± 11 years; men, 45.2%); and group V, GFR \< 15 mL/min/1.73 m^2^ (123 patients; age, 66 ± 13 years; men, 64.2%).

Data collection
---------------

The baseline variables included age; gender; body mass index (BMI); and several coronary risk factors such as hypertension (defined as history of hypertension and admission blood pressure \> 140 mm Hg systolic or \> 90 mm Hg diastolic), DM (defined as history of DM or random blood glucose level \> 200 mg/dL), hyperlipidemia (defined as history of hyperlipidemia, total cholesterol level of \> 240 mg/dL, or low density lipoprotein \[LDL\] level \> 101 mg/dL), history of smoking, history of ischemic heart disease (IHD), clinical symptoms at admission (chest pain or dyspnea), and Killip class. One of the following 3 modalities was selected as primary reperfusion therapy for patients with STEMI: intravenous thrombolytic therapy, primary PCI, or facilitated PCI. The use of certain medications (aspirin, clopidogrel, ACE inhibitor, ARB, β-blocker or statin) during the in-hospital period and at discharge was also recorded. MACE was defined as a composite outcome of cardiac death, repeated PCI, or MI.

Statistical analysis
--------------------

Continuous variables with normal distributions are expressed as mean ± SD, and the 5 groups were compared using one-way ANOVA. Continuous data with a skewed distribution are presented as median (with 25th and 75th percentiles) and were compared using the Kruskal-Wallis test. Categorical variables were compared using the chi-square test or the Fisher's exact test if the expected value of the variable was \<5 in at least 1 group. Survival analysis after MI was estimated using the Kaplan-Meier method with log-rank tests to compare survival among groups. All statistical tests were 2-tailed, and p \< 0.05 was considered significant. Analyses were performed using the Statistical Package for Social Sciences software, version 18.0 (IBM, Armonk, NY USA).

Results
=======

Baseline characteristics
------------------------

A total of 7,679 patients (age, 63 ± 13 years; men, 73.6%) were included in the present study. The baseline characteristics and biochemical parameters of patients are shown in Table[1](#T1){ref-type="table"}. A lower GFR was associated with older age, female gender, higher prevalence of hypertension, DM, history of IHD, and lower likelihood of being a current smoker. At the time of hospital arrival, a lower GFR was associated with lower blood pressure, lower left ventricular ejection fraction (LVEF), and higher Killip class. In patients with lower GFR, the total cholesterol, LDL, triglyceride, troponin-I, and creatine kinase-MB (CK-MB) levels were lower, whereas the glucose, high sensitivity C-reactive protein (hs-CRP), N-terminal prohormone of brain natriuretic peptide (NT-pro BNP) levels were higher than in patients with higher GFR.

###### 

Baseline characteristics

                                **Group I (n = 2099)**   **Group II (n = 3647)**   **Group III (n = 1600)**   **Group IV (n = 210)**   **Group V (n = 123)**   ***P*value**
  ---------------------------- ------------------------ ------------------------- -------------------------- ------------------------ ----------------------- --------------
  Age, years                           54 ± 11                   63 ± 12                   71 ± 11                   73 ± 11                  66 ± 13            \<0.001
  Male                                1745(83.1)               2763(75.8)                 970(60.6)                  95(45.2)                79(64.2)            \<0.001
  BMI, kg/m^2^                          24 ± 3                   24 ± 3                     24 ± 3                    23 ± 3                  24 ± 3              0.284
  **Past History**                                                                                                                                            
  Hypertension                        739(35.3)                1571(43.2)                 953(59.8)                 156(74.6)                75(61.5)            \<0.001
  DM                                  445(21.3)                 789(21.7)                 505(31.7)                  99(47.6)                60(48.8)            \<0.001
  Previous IHD                         190(9.1)                 420(11.6)                 239(15.1)                  39(18.8)                29(23.6)            \<0.001
  Hyperlipidemia                       184(8.8)                 273(7.5)                   121(7.6)                  17(8.1)                  8(6.6)              0.171
  Smoking                             1276(61.1)               1779(49.1)                 493(31.2)                  53(25.9)                39(32.2)            \<0.001
  **At admission**                                                                                                                                            
  SBP (mmHg)                           130 ± 26                 127 ± 28                   117 ± 33                  111 ± 36                123 ± 35            \<0.001
  DBP (mmHg)                           81 ± 16                   78 ± 17                   72 ± 19                   70 ± 23                  75 ± 21            \<0.001
  Killip class                        1.3 ± 0.7                 1.4 ± 0.8                 1.8 ± 1.1                 2.1 ± 1.2                2.0 ± 1.2           \<0.001
  LVEF (%)                             52 ± 11                   51 ± 12                   48 ± 13                   47 ± 14                  47 ± 12            \<0.001
  **Biochemical parameters**                                                                                                                                  
  Creatinine (mg/dL)                  0.8 ± 0.1                 1.0 ± 0.2                 1.4 ± 0.3                 2.3 ± 0.5                9.5 ± 8.9           \<0.001
  Troponin-I (ng/mL)                   40(9,79)                 30(7,68)                   28(5,73)                 31(10,56)                28(6,51)             0.007
  CK-MB (U/L)                        133(38,277)               132(40,283)               112(26,243)                84(27,195)              69(20,176)           \<0.001
  TC (mg/dL)                           188 ± 44                 183 ± 43                   175 ± 45                  165 ± 42                174 ± 60             0.004
  LDL (mg/dL)                          122 ± 42                 116 ± 42                   112 ± 41                  100 ± 39                106 ± 52             0.026
  TG (mg/dL)                         109(72,163)               98(66,143)                 95(66,140)               105(74,152)              91(66,150)           \<0.001
  Glucose (mg/dL)                      161 ± 66                 168 ± 70                  201 ± 100                 234 ± 134                201 ± 106           \<0.001
  hs-CRP (mg/dL)                     0.6(0.2,3.4)             0.8(0.2,4.2)               1.3(0.3,7.0)             4.6(0.8,15.0)            2.1(0.6,9.8)          \<0.001
  NT-proBNP (pg/mL)                  223 (57,871)             346 (75,1414)            1144 (230,3973)          5423 (1296,21374)       21191 (4957,35000)       \<0.001

Continuous data are expressed as the mean ± SD or the median and interquartile range (25th and 75th percentiles). Categorical data were expressed as percentages. Abbreviations: BMI, body mass index; DM, diabetes mellitus; IHD, ischemic heart disease; SBP, systolic blood pressure; DBP, diastolic blood pressure; LVEF, left ventricular ejection fraction; CK-MB, creatine kinase-MB; TC, total cholesterol; LDL, low density lipoprotein; hs-CRP, high-sensitivity C-reactive protein; NT-proBNP, N-terminal pro B-type natriuretic peptide.

Delayed timely restoration of flow in the stenosed artery
---------------------------------------------------------

Patients with lower GFRs were less likely to present with typical chest pain. The time to restoration of flow in the stenosed artery was analyzed in the following ways: symptom-to-door time in all patients; door-to-balloon time and symptom-to-balloon time in patients who underwent primary PCI as initial reperfusion therapy; door-to-needle time and symptom-to-needle time in patients who received thrombolysis as initial reperfusion therapy (Table[2](#T2){ref-type="table"}). Patients with lower GFRs tended to have longer symptom-to-door times. In patients with lower GFRs, door-to-balloon time and symptom-to-balloon time also tended to be longer when primary PCI was the initial reperfusion therapy. In contrast, door-to-needle time and symptom-to-needle time were not significantly different in patients with lower GFRs.

###### 

Presence of typical chest pain and time of restoration of infarcted-artery

                                 **Group I**    **Group II**    **Group III**   **Group IV**     **Group V**    ***P*value**
  ---------------------------- --------------- --------------- --------------- --------------- --------------- --------------
  Presence of chest pain         1916(91.8)      3215(88.7)      1305(82.2)       154(74.4)       80(66.1)        \<0.001
  Symptom to door time, hr      3.5(1.8,7.7)    3.3(1.6,8.2)    3.8(1.8,9.7)    5.4(2.1,15.5)   4.8(1.8,16.1)     \<0.001
  **Primary PCI** †                                                                                            
  Door to ballon time, hr       1.5(1.1,2.9)    1.5(1.0,2.3)    1.5(1.1,2.4)    1.7(1.2,2.6)    1.9(1.3,4.6)      \<0.001
  Symptom to ballon time, hr    5.6(3.4,13.0)   4.8(3.1,10.1)   5.4(3.3,10.8)   8.3(4.2,18.4)   7.2(3.3,26.0)     \<0.001
  **Thrombolysis** ‡                                                                                           
  Door to needle time, hr       0.9(0.6,1.5)    0.9(0.6,1.4)    0.9(0.6,1.4)    1.2(0.4,5.8)     0.8(0.4,-)        0.876
  Symptom to needle time, hr    3.5(2.2,5.0)    3.4(2.4,5.1)    3.4(2.4,5.1)    5.0(4.1,9.0)     11.0(0.8,-)       0.316

Continuous data are expressed as the median and interquartile range (25th and 75th percentiles). Categorical data were expressed as percentages. Abbreviations: PCI, percutaneous intervenyion;

† The subject who received primary reperfusion therapy as primary percutaneous intervention (PCI), (n = 5,607).

‡ The subject who received primary reperfusion therapy as thrombolytic therapy, (n = 618).

Initial treatment strategy and results of reperfusion therapy
-------------------------------------------------------------

In the initial selection of treatment strategy in patients with STEMI, conservative treatment was more commonly performed but thrombolysis was less frequently performed in patients with lower GFRs (Figure[1](#F1){ref-type="fig"}). During the in-hospital period, PCI, regardless of its subtype (primary PCI, facilitated PCI, or rescue PCI), was less frequently performed in patients with lower GFR, and its success rate markedly decreased with decrease in GFR (Table[3](#T3){ref-type="table"}). In addition, thrombolysis was also performed less frequently in patients with lower GFR, and the success rate of thrombolysis decreased with decrease in GFR.

![Initial reperfusion strategy in STEMI patients.](1471-2369-13-110-1){#F1}

###### 

Results of reperfusion therapy

                                  **Group I**   **Group II**   **Group III**   **Group IV**   **Group V**   ***P*value**
  ------------------------------ ------------- -------------- --------------- -------------- ------------- --------------
  **Result of PCI** †                                                                                      
  Patients, n                     1974(95.9)     3406(94.9)     1437(91.3)      181(87.4)      104(86.0)      \<0.001
  Success                         1832(92.8)     3139(92.2)     1286(89.5)      151(83.4)      86(82.7)       \<0.001
  Suboptimal                        40(2.0)       83(2.3)         44(3.1)         6(3.3)        5(4.8)            
  Failed                           102(5.2)       184(5.4)       107(7.4)        24(13.3)      13(12.5)           
  **Result of thrombolysis** ‡                                                                             
  Patients, n                      290(14.0)     367(10.2)       119(7.5)        11(5.3)        6(5.0)        \<0.001
  Success                          222(76.6)     262(71.4)       83(69.7)        3(27.3)        3(50.0)        0.003
  Failed                           68(23.4)      105(28.6)       36(30.3)        8(72.7)        3(50.0)           

Data are presented as number of patients (percentage). Abbreviations: PCI, percutaneous intervention.

† The subject who received PCI during in-hospital period regardless of its subtype (primary PCI, facilitated PCI, rescue PCI), (n = 7,102).

‡ The subject who received thrombolysis therapy during in-hospital period (thrombolysis only, facilitated PCI), (n = 793).

Angiographic finding
--------------------

Angiographic findings are shown in Table[4](#T4){ref-type="table"}. Multivessel coronary artery disease and disease of the left main coronary artery were more common in groups with lower GFR. Initial TIMI flow 0 (no flow) and presence of a complex lesion (type C) were more frequently observed and a final TIMI flow 3 (complete perfusion) was less frequently observed with lower GFR. Patients with lower GFR were treated with a greater number of stents than patients with higher GFRs.

###### 

Angiographic data

                               **Group I**   **Group II**   **Group III**   **Group IV**   **Group V**   ***P*value**
  --------------------------- ------------- -------------- --------------- -------------- ------------- --------------
  **Number of vessel**                                                                                  
  One vessel                   1044(53.2)     1599(47.2)      508(35.6)       42(23.3)      31(30.1)       \<0.001
  Two vessel                    527(26.9)     1035(30.6)      466(32.7)       66(36.7)      30(29.1)       \<0.001
  Three vessel                  354(18.1)     682(20.1)       405(28.4)       62(34.4)      35(34.0)       \<0.001
  LM                             36(1.8)       70(2.1)         47(3.3)        10(5.6)        7(6.8)        \<0.001
  ACC/AHA lesion C              903(48.9)     1625(51.4)      714(53.8)      108(65.5)      57(59.4)       \<0.001
  Initial TIMI flow grade 0     938(49.7)     1763(54.1)      772(56.1)      102(59.3)      41(41.8)        0.007
  Final TIMI flow grade 3      1728(94.3)     2913(91.6)     1181(88.1)      139(84.2)      76(81.7)       \<0.001
  Stent number                 1.40 ± 0.74   1.44 ± 0.77     1.48 ± 0.81    1.49 ± 0.75    1.52 ± 0.88      0.002
  Stent diameter, mm           3.21 ± 0.42   3.21 ± 0.44     3.15 ± 0.45    3.10 ± 0.43    3.22 ± 0.42      0.655
  Stent length, mm             25.0 ± 6.3     25.1 ± 6.2     25.3 ± 6.4      26.4 ± 6.8    24.7 ± 6.5       0.802

Data are presented as mean ± SD or number of patients (percentage). Abbreviations: TIMI, Thrombolysis In Myocardial Infarction.

Intensity of medical treatment
------------------------------

Table[5](#T5){ref-type="table"} lists specific medical treatments received prior to PCI, both during the in-hospital period and at discharge, according to GFR. The use of an anti-platelet agent prior to PCI was not significantly different among the groups. During in-hospital periods, standard medications known to improve survival after MI, such as anti-platelet agent, β-blocker, ACE inhibitor or ARB, and statin were less frequently used in patients with lower GFR. The underuse of these drugs was not corrected until hospital discharge of the patients who survived STEMI. We evaluated the correlation between clinical outcomes and intensity of evidence-based medication in patients with GFR \< 60 mL/min/1.73 m^2^. In the hospital period, the patients who received less intense medical therapies had worse clinical outcomes than those who received more intense medical therapies. Similar observations were made for discharge medications among patients who survived STEMI (Figure[2](#F2){ref-type="fig"}).

###### 

Intense of medical therapy

                                **Group I**   **Group II**   **Group III**   **Group IV**   **Group V**   ***P*value**
  ---------------------------- ------------- -------------- --------------- -------------- ------------- --------------
  **Pre-PCI medication**                                                                                 
  Patients, n                      1974           3406           1437            181            104            96
  Aspirin                        796(40.3)     1366(40.1)      565(39.3)       76(42.0)      53(51.0)        0.476
  Clopidogrel                    748(37.9)     1299(38.1)      528(36.7)       71(39.2)      49(47.1)        0.622
  **In-hospital medication**                                                                             
  Patients, n                      2099           3647           1600            210            123             
  Aspirin                       2069(98.6)     3594(98.5)     1544(96.5)      197(93.8)      118(95.9)      \<0.001
  Clopidogrel                   2048(97.6)     3540(97.1)     1522(95.1)      192(91.4)      114(92.7)      \<0.001
  β-blocker                     1619(77.1)     2581(70.8)     1003(62.7)      115(54.8)      71(57.7)       \<0.001
  ACEi or ARB                   1754(83.6)     2906(79.7)     1165(72.8)      132(62.9)      73(59.3)       \<0.001
  Statin                        1630(77.7)     2716(74.5)     1034(64.6)      125(59.5)      79(64.2)       \<0.001
  **Discharge medication**                                                                               
  Patients, n                      2067           3519           1373            151            91              
  Aspirin                       1980(95.8)     3390(96.3)     1303(94.9)      139(92.1)      86(94.5)        0.054
  Clopidogrel                   1927(93.2)     3276(93.1)     1266(92.2)      131(86.8)      81(89.0)        0.012
  β-blocker                     1528(73.9)     2412(68.5)      921(67.1)       99(65.6)      58(63.7)       \<0.001
  ACEi or ARB                   1691(81.8)     2789(79.3)     1070(77.9)      105(69.5)      66(72.5)       \<0.001
  Statin                        1577(76.3)     2610(74.2)      941(68.5)      101(66.9)      61(67.0)       \<0.001

Data are presented as number of patients (percentage). Abbreviations: PCI, percutaneous coronary intervention; ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker.

![**Kaplan-Meier estimates of cumulative survival according to intense of medical therapies.** (**A**) 1 month cumulative survival according to intense of in-hospital medications (**B**) 1 year cumulative survival according to intense of discharge medications; medications^†^, sum of prescription of aspirin, clopidogrel, beta-blocker, angiotensin converting enzyme inhibitor or angiotensin receptor blocker and statin.](1471-2369-13-110-2){#F2}

Outcomes according to GFR
-------------------------

The clinical outcomes in patients with STEMI are listed in Table[6](#T6){ref-type="table"}. At 1 month, MACE and all-cause death were higher in patients with lower GFRs. At 12 months, MACE and all-cause death also increased as decreasing GFRs.

###### 

Outcomes according to the GFR

                           **Group I**   **Group II**   **Group III**   **Group IV**   **Group V**   ***P*value**
  ----------------------- ------------- -------------- --------------- -------------- ------------- --------------
  **1 month outcomes**                                                                              
  MACE                       64(3.5)       217(6.9)       284(20.6)       74(41.8)      37(35.2)       \<0.001
  All-cause death            41(2.0)       160(4.4)       263(16.4)       71(33.8)      35(28.5)       \<0.001
  **12 month outcomes**                                                                             
  MACE                      183(8.7)      382(10.5)       351(21.9)       78(37.1)      46(37.4)       \<0.001
  All-cause death            60(4.4)       195(8.2)       304(27.1)       79(54.9)      41(48.8)       \<0.001

Data are presented as number of patients (percentage). Abbreviations: MACE, major adverse cardiovascular event.

Discussions
===========

The principal finding of this study is that patients who have renal insufficiency and develop STEMI are less likely to receive optimal therapy. Patients with renal insufficiency more often presented with atypical symptoms and had longer delays in both hospital arrival and reperfusion. In addition, primary reperfusion therapy was performed less frequently in patients with renal insufficiency and the results of reperfusion therapy were worse with lower GFR. Patients with renal insufficiency were less likely to receive life-saving medical medications such as anti-platelet agent, β-blocker, ACE inhibitor/ARB, or statin during hospitalization and at discharge.

A recent study reported that the probability of patients with MI presenting without chest pain increased proportionally with a decrease in GFR \[[@B8]\]. Canto et al. also showed that patients with MI, but without chest pain, are at increased risk for delays in seeking medical attention, less aggressive treatment, and have higher associated in-hospital mortality \[[@B9]\]. Taken together, these findings suggest that patient with renal insufficiency may have less chance of receiving timely medical care, which may in part be attributed to lack of chest pain. A delay in the time to restoration of flow in the stenosed artery was also observed with lower GFR in patients who had STEMI and underwent primary PCI. Rapid reperfusion is an important goal in the treatment of STEMI patients \[[@B10],[@B11]\]. However, patients with renal insufficiency arrived at the hospital relatively late with respect to symptom onset, and clinicians may be reluctant to make an immediate decision in patients with renal insufficiency because of the presence of more comorbidities and increased complexity of medical care.

During the hospital period, reperfusion therapy, regardless of its subtype, was used less frequently in patients with lower GFR, which was consistent with previous studies \[[@B12],[@B13]\]. Older age, more comorbidities, compromised hemodynamic status, and fear of complications such as bleeding and contrast-induced nephropathy may all affect a clinician's decision. In addition, the results of reperfusion therapy were disappointing in patients with renal insufficiency. A higher incidence of multivessel disease, more complex lesions, and poor coronary blood flow before and after PCI may contribute to the poor results of reperfusion therapy. Although the exact pathophysiologic mechanisms by which renal insufficiency adversely affect the results of reperfusion therapy have not been clearly elucidated, oxidative stress, endothelial cell dysfunction, and more advanced atherosclerosis may play a role in this regard \[[@B14]-[@B17]\].

Although, renal insufficiency is an important risk factor for increased mortality, patients with lower GFR were less likely to receive adjunctive medical therapies recommended by current guidelines. This finding is consistent with previous reports \[[@B18],[@B19]\]. The underuse of life-saving medications may result from fear of adverse effects. Clinicians are often reluctant to use an anti-platelet agent for patients with renal insufficiency because of the risk of bleeding. Similarly, hyperkalemia or renal function deterioration often pushes clinicians to withhold ACE inhibitor/ARB therapy. However, evidence indicates that these medications are associated with great survival benefits in patients with renal insufficiency, even in the case of severe renal insufficiency \[[@B20]-[@B22]\]. In clinical practice, clinicians who assess the risks and benefits of medication should consider the fact that the long-term cardioprotective and survival benefits outweigh the risk associated with short-term adverse effects.

The mortality rate associated with MI has fallen considerably in recent decades \[[@B23],[@B24]\]. Improvements in emergency system response times and diagnostic techniques may explain some of the improvements in MI mortality. Advances in medical treatment and cardiac interventions have also played a role in this improvement. Despite these advances, data from this study indicate that patients with renal insufficiency were less likely to receive optimal medical care throughout the entire process of MI management and that these differences may contribute to worse outcomes in patients from the KAMIR data population who had lower GFR and developed MI \[[@B4],[@B25]\].

The present study has some limitations. First, KAMIR is a multicenter retrospective registry study and not a randomized controlled study. Therefore, unmeasured factors in the KAMIR database could influence these findings. Second, assessment of kidney function in this study was based on a single serum creatinine value obtained at the time of presentation to the hospital. This value may have been affected by hemodynamic or metabolic status. Third, although, estimating GFR based on serum creatinine are preferable method for accessing renal function in the clinical practice, it is influenced by various factors such as age, gender, ethnics, muscle mass and nutritional status. This could confound the relationship between GFR and likelihood of receiving optimal medical care in patients with STEMI.

Conclusion
==========

In conclusion, patients with STEMI and renal insufficiency had significantly less chance of receiving optimal medical care throughout the entire process of MI management. Despite recent advances in emergency systems and evidence-based therapy, these advances have been applied less frequently in patients with renal insufficiency than in patients with normal renal function. Therefore, patients with renal insufficiency require an aggressive approach to diagnosis, intervention, and medical treatment for improved clinical outcomes.
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Seoul St.Mary\'s Hospital, Kangdong Sacred Hospital, Konyang University Hospital, Kyungpook National University Hospital, Gyeongsang National University Hospital, Kyunghee Dongsuh University Hospital, Kyunghee University Medical Center, Korea University Guro Hospital, Kwangju Christian Hospital, National Health Insurance Corporation Ilsan Hospital, Dankook University Hospital, Daegu Catholic University Medical Center, Daejeon Sun Hospital, Daejeon St.Mary\'s Hospital, Dongguk University Gyeongju Hospital, Dongsan Medical Center, Dong-A University Medical Center, Mokpo Hankuk Hospital, Kwangju Veterans Hospital, Busan National University Hospital, Busan Marynoll Medical Center, Busan Paik Hospital, Busan Hanseo Hospital, Seoul National University Bundang Hospital, Samsung Medical Center, Inje University Sanggye Paik Hospital, Seoul National University Hospital, Asan Medical Center, St. Paul\'s Hospital, St. Carollo Hospital, Soon Chun Hyang University Bucheon Hospital, Soon Chun Hyang University Cheonan Hospital, Yonsei University Severance Hospital, Ajou University Hospital, Yeouido St.Mary\'s Hospital, Yeungnam University Medical Center, Wonkwang University School of Medicine & Hospital, Wonju University Hospital, Eulji Medical Center, Ewha Womans University Mokdong Hospital, Gachon University Gil Hospital, Inha University Hospital, Chonnam National University Hospital, Chonbuk National University Hospital, Presbyterian Medical Center, Jeju National University Hospital, Chosun University Hospital, Chung Ang University Hospital, Chungnam National University Hospital, Chungbuk National University Hospital, Pohang Seomyung Christianity Hospital, Hallym University Medical Center.
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